PS-068 Evaluation of the incidence and the consequences of the extravasation of chemotherapy drugs in a tertiary hospital
BackgroundCytostatic extravasation is the inadvertent leakage of intravenous anticancer agents out of the vein into surrounding tissue. Extravasation is only considered to be problematic with chemotherapy drugs known to have irritant or vesicant attributes. Depending on the substance that is extrava...
Gespeichert in:
Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2016-03, Vol.23 (Suppl 1), p.A243-A244 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A244 |
---|---|
container_issue | Suppl 1 |
container_start_page | A243 |
container_title | European journal of hospital pharmacy. Science and practice |
container_volume | 23 |
creator | Alonso, A Martín Bravo, A de Rivas Manrique, M Manso Prieto, E Santiago Guerrero, A Sánchez |
description | BackgroundCytostatic extravasation is the inadvertent leakage of intravenous anticancer agents out of the vein into surrounding tissue. Extravasation is only considered to be problematic with chemotherapy drugs known to have irritant or vesicant attributes. Depending on the substance that is extravasated into the tissue, the degree of injury can range from a very mild skin reaction to severe necrosis.PurposeTo evaluate the incidence, types of anticancer agents involved and consequences of extravasation.Material and methodsObservational, retrospective study, from March 2010 to October 2015, of all patients who suffered an extravasation during the infusion of chemotherapy drugs in a tertiary hospital.Data were obtained from the electronic medical history and the extravasation database. Data collected were demographics, date of extravasation, type of cytostatic agent infused, infusion time until extravasation, extravasation area and local reactions.ResultsThe study included 24 patients (58.3% males), mean age 62.7 years (18–81). All extravasations were resolved by following the procedures of the extravasation protocol established in our hospital. Among 61 463 patients who received chemotherapy, 24 (0.04%) experienced extravasation.The chemotherapy drugs involved in the extravasation were paclitaxel (7), etoposide (4), oxaliplatin (3), docetaxel (3), carboplatin (2), vinorelbine (2), dacarbazine (2), 5-fluorouracil (1) and cisplatin (1). According to the ESMO–EONS Clinical Practice Guidelines, 15 drugs were irritants and 9 vesicants.The mean duration between the start of infusion and extravasation was 46 min (2–240). The average extravasation area was 22.1 cm2 (4–84). Of the 24 patients, 20 experienced induration or swelling at the injection site, 11 erythema, 4 pain and 1 burning.ConclusionThe incidence of extravasation in our study was very low (0.04%). This result agrees with other incidence rates published in several studies, which vary greatly from 0.01% to 7%.All extravasations were cured without surgical intervention by management according to our guidelines.Despite the irritants and vesicants of the chemotherapy drugs involved, patients only suffered mild skin reactions.References and/or AcknowledgementsManagement of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl 7):vii167–vii173, doi:10.1093/annonc/mds294.No conflict of interest. |
doi_str_mv | 10.1136/ejhpharm-2016-000875.552 |
format | Article |
fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2552750567</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552750567</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1007-9df43f09f18a7c0891afcb72770dac6b3d943fc12dca16fc650715bce4b09b3a3</originalsourceid><addsrcrecordid>eNp9UctOwzAQtBBIVKX_YIlzyjqO7eSIqvKQKoEEnC3bcUiq5oGdVFRcuPCjfAkOpT1y2tXu7MzuDkKYwJwQyq_suuxK5eooBsIjAEgFmzMWn6BJDImIsownp8ec8XM0877SwChNs4RmE_Tx-BQBT78_v5ZbtRlUX7UNbgvclxZXjaly2xiLVZP_VkzbePs2jDV_QNn33qmt8sdRU9q6DR2nuh3O3fDqAxNWuLeur5Tb4bL1XdWrzQU6K9TG29lfnKKXm-Xz4i5aPdzeL65XkSYAYfG8SGgBWUFSJQykGVGF0SIWAnJluKZ5OKUwJM6NIrwwnIEgTBubaMg0VXSKLve8nWvD8r6X63ZwTZCUcXiWYMC4-A9FRJqwwClGFN2jdL2WnavqcJAkIEc75MEOOdoh93bIoEB_AHNVgdg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1784571577</pqid></control><display><type>article</type><title>PS-068 Evaluation of the incidence and the consequences of the extravasation of chemotherapy drugs in a tertiary hospital</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Alonso, A Martín ; Bravo, A de Rivas ; Manrique, M Manso ; Prieto, E Santiago ; Guerrero, A Sánchez</creator><creatorcontrib>Alonso, A Martín ; Bravo, A de Rivas ; Manrique, M Manso ; Prieto, E Santiago ; Guerrero, A Sánchez</creatorcontrib><description>BackgroundCytostatic extravasation is the inadvertent leakage of intravenous anticancer agents out of the vein into surrounding tissue. Extravasation is only considered to be problematic with chemotherapy drugs known to have irritant or vesicant attributes. Depending on the substance that is extravasated into the tissue, the degree of injury can range from a very mild skin reaction to severe necrosis.PurposeTo evaluate the incidence, types of anticancer agents involved and consequences of extravasation.Material and methodsObservational, retrospective study, from March 2010 to October 2015, of all patients who suffered an extravasation during the infusion of chemotherapy drugs in a tertiary hospital.Data were obtained from the electronic medical history and the extravasation database. Data collected were demographics, date of extravasation, type of cytostatic agent infused, infusion time until extravasation, extravasation area and local reactions.ResultsThe study included 24 patients (58.3% males), mean age 62.7 years (18–81). All extravasations were resolved by following the procedures of the extravasation protocol established in our hospital. Among 61 463 patients who received chemotherapy, 24 (0.04%) experienced extravasation.The chemotherapy drugs involved in the extravasation were paclitaxel (7), etoposide (4), oxaliplatin (3), docetaxel (3), carboplatin (2), vinorelbine (2), dacarbazine (2), 5-fluorouracil (1) and cisplatin (1). According to the ESMO–EONS Clinical Practice Guidelines, 15 drugs were irritants and 9 vesicants.The mean duration between the start of infusion and extravasation was 46 min (2–240). The average extravasation area was 22.1 cm2 (4–84). Of the 24 patients, 20 experienced induration or swelling at the injection site, 11 erythema, 4 pain and 1 burning.ConclusionThe incidence of extravasation in our study was very low (0.04%). This result agrees with other incidence rates published in several studies, which vary greatly from 0.01% to 7%.All extravasations were cured without surgical intervention by management according to our guidelines.Despite the irritants and vesicants of the chemotherapy drugs involved, patients only suffered mild skin reactions.References and/or AcknowledgementsManagement of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl 7):vii167–vii173, doi:10.1093/annonc/mds294.No conflict of interest.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2016-000875.552</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Cancer ; Chemotherapy ; Clinical medicine ; Drugs</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A243-A244</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2016 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Alonso, A Martín</creatorcontrib><creatorcontrib>Bravo, A de Rivas</creatorcontrib><creatorcontrib>Manrique, M Manso</creatorcontrib><creatorcontrib>Prieto, E Santiago</creatorcontrib><creatorcontrib>Guerrero, A Sánchez</creatorcontrib><title>PS-068 Evaluation of the incidence and the consequences of the extravasation of chemotherapy drugs in a tertiary hospital</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundCytostatic extravasation is the inadvertent leakage of intravenous anticancer agents out of the vein into surrounding tissue. Extravasation is only considered to be problematic with chemotherapy drugs known to have irritant or vesicant attributes. Depending on the substance that is extravasated into the tissue, the degree of injury can range from a very mild skin reaction to severe necrosis.PurposeTo evaluate the incidence, types of anticancer agents involved and consequences of extravasation.Material and methodsObservational, retrospective study, from March 2010 to October 2015, of all patients who suffered an extravasation during the infusion of chemotherapy drugs in a tertiary hospital.Data were obtained from the electronic medical history and the extravasation database. Data collected were demographics, date of extravasation, type of cytostatic agent infused, infusion time until extravasation, extravasation area and local reactions.ResultsThe study included 24 patients (58.3% males), mean age 62.7 years (18–81). All extravasations were resolved by following the procedures of the extravasation protocol established in our hospital. Among 61 463 patients who received chemotherapy, 24 (0.04%) experienced extravasation.The chemotherapy drugs involved in the extravasation were paclitaxel (7), etoposide (4), oxaliplatin (3), docetaxel (3), carboplatin (2), vinorelbine (2), dacarbazine (2), 5-fluorouracil (1) and cisplatin (1). According to the ESMO–EONS Clinical Practice Guidelines, 15 drugs were irritants and 9 vesicants.The mean duration between the start of infusion and extravasation was 46 min (2–240). The average extravasation area was 22.1 cm2 (4–84). Of the 24 patients, 20 experienced induration or swelling at the injection site, 11 erythema, 4 pain and 1 burning.ConclusionThe incidence of extravasation in our study was very low (0.04%). This result agrees with other incidence rates published in several studies, which vary greatly from 0.01% to 7%.All extravasations were cured without surgical intervention by management according to our guidelines.Despite the irritants and vesicants of the chemotherapy drugs involved, patients only suffered mild skin reactions.References and/or AcknowledgementsManagement of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl 7):vii167–vii173, doi:10.1093/annonc/mds294.No conflict of interest.</description><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Drugs</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9UctOwzAQtBBIVKX_YIlzyjqO7eSIqvKQKoEEnC3bcUiq5oGdVFRcuPCjfAkOpT1y2tXu7MzuDkKYwJwQyq_suuxK5eooBsIjAEgFmzMWn6BJDImIsownp8ec8XM0877SwChNs4RmE_Tx-BQBT78_v5ZbtRlUX7UNbgvclxZXjaly2xiLVZP_VkzbePs2jDV_QNn33qmt8sdRU9q6DR2nuh3O3fDqAxNWuLeur5Tb4bL1XdWrzQU6K9TG29lfnKKXm-Xz4i5aPdzeL65XkSYAYfG8SGgBWUFSJQykGVGF0SIWAnJluKZ5OKUwJM6NIrwwnIEgTBubaMg0VXSKLve8nWvD8r6X63ZwTZCUcXiWYMC4-A9FRJqwwClGFN2jdL2WnavqcJAkIEc75MEOOdoh93bIoEB_AHNVgdg</recordid><startdate>201603</startdate><enddate>201603</enddate><creator>Alonso, A Martín</creator><creator>Bravo, A de Rivas</creator><creator>Manrique, M Manso</creator><creator>Prieto, E Santiago</creator><creator>Guerrero, A Sánchez</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201603</creationdate><title>PS-068 Evaluation of the incidence and the consequences of the extravasation of chemotherapy drugs in a tertiary hospital</title><author>Alonso, A Martín ; Bravo, A de Rivas ; Manrique, M Manso ; Prieto, E Santiago ; Guerrero, A Sánchez</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1007-9df43f09f18a7c0891afcb72770dac6b3d943fc12dca16fc650715bce4b09b3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alonso, A Martín</creatorcontrib><creatorcontrib>Bravo, A de Rivas</creatorcontrib><creatorcontrib>Manrique, M Manso</creatorcontrib><creatorcontrib>Prieto, E Santiago</creatorcontrib><creatorcontrib>Guerrero, A Sánchez</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alonso, A Martín</au><au>Bravo, A de Rivas</au><au>Manrique, M Manso</au><au>Prieto, E Santiago</au><au>Guerrero, A Sánchez</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PS-068 Evaluation of the incidence and the consequences of the extravasation of chemotherapy drugs in a tertiary hospital</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2016-03</date><risdate>2016</risdate><volume>23</volume><issue>Suppl 1</issue><spage>A243</spage><epage>A244</epage><pages>A243-A244</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundCytostatic extravasation is the inadvertent leakage of intravenous anticancer agents out of the vein into surrounding tissue. Extravasation is only considered to be problematic with chemotherapy drugs known to have irritant or vesicant attributes. Depending on the substance that is extravasated into the tissue, the degree of injury can range from a very mild skin reaction to severe necrosis.PurposeTo evaluate the incidence, types of anticancer agents involved and consequences of extravasation.Material and methodsObservational, retrospective study, from March 2010 to October 2015, of all patients who suffered an extravasation during the infusion of chemotherapy drugs in a tertiary hospital.Data were obtained from the electronic medical history and the extravasation database. Data collected were demographics, date of extravasation, type of cytostatic agent infused, infusion time until extravasation, extravasation area and local reactions.ResultsThe study included 24 patients (58.3% males), mean age 62.7 years (18–81). All extravasations were resolved by following the procedures of the extravasation protocol established in our hospital. Among 61 463 patients who received chemotherapy, 24 (0.04%) experienced extravasation.The chemotherapy drugs involved in the extravasation were paclitaxel (7), etoposide (4), oxaliplatin (3), docetaxel (3), carboplatin (2), vinorelbine (2), dacarbazine (2), 5-fluorouracil (1) and cisplatin (1). According to the ESMO–EONS Clinical Practice Guidelines, 15 drugs were irritants and 9 vesicants.The mean duration between the start of infusion and extravasation was 46 min (2–240). The average extravasation area was 22.1 cm2 (4–84). Of the 24 patients, 20 experienced induration or swelling at the injection site, 11 erythema, 4 pain and 1 burning.ConclusionThe incidence of extravasation in our study was very low (0.04%). This result agrees with other incidence rates published in several studies, which vary greatly from 0.01% to 7%.All extravasations were cured without surgical intervention by management according to our guidelines.Despite the irritants and vesicants of the chemotherapy drugs involved, patients only suffered mild skin reactions.References and/or AcknowledgementsManagement of chemotherapy extravasation: ESMO–EONS Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl 7):vii167–vii173, doi:10.1093/annonc/mds294.No conflict of interest.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2016-000875.552</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2047-9956 |
ispartof | European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A243-A244 |
issn | 2047-9956 2047-9964 |
language | eng |
recordid | cdi_proquest_journals_2552750567 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Cancer Chemotherapy Clinical medicine Drugs |
title | PS-068 Evaluation of the incidence and the consequences of the extravasation of chemotherapy drugs in a tertiary hospital |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T04%3A56%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PS-068%E2%80%85Evaluation%20of%20the%20incidence%20and%20the%20consequences%20of%20the%20extravasation%20of%20chemotherapy%20drugs%20in%20a%20tertiary%20hospital&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Alonso,%20A%20Mart%C3%ADn&rft.date=2016-03&rft.volume=23&rft.issue=Suppl%201&rft.spage=A243&rft.epage=A244&rft.pages=A243-A244&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2016-000875.552&rft_dat=%3Cproquest_bmj_p%3E2552750567%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1784571577&rft_id=info:pmid/&rfr_iscdi=true |